Dose-Escalated MR-Guided Radiotherapy for Localized Prostate Cancer

DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.

NCT Number	NCT07674225
Lead Sponsor	Sunnybrook Health Sciences Centre Collaborators: Elekta Limited, MRL Consortium
Conditions	Intermediate Risk Prostate Cancer (Diagnosis), Prostate Cancer
Enrollment	24 participants
Start Date	2026-03-22
Primary Completion	2028-06-01 (estimated)
Study Completion	2030-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-29